Global Clinical Trials for Alzheimer's Disease. Design, Implementation, and Standardization

Content: 
Front-matter, Page i
Copyright, Page ii
International Editorial Advisors, Pages iii-iv
Preface, Pages xiii-xiv, Menghis Bairu, Michael W. Weiner
About the Editors, Pages xv-xvi
List of Contributors, Pages xvii-xviii, Susan Abushakra, Ricardo F. Allegri, H. Michael Arrighi, Pablo M. Bagnati, Menghis Bairu, Sonia Brucki, Tal Burt, Lorne Cheeseman, Richard Chin, Debbie N. Cote, Jeffrey Cummings, Stephanie Danandjaja, P. Murali Doraiswamy, Murat Emre, James (Dachao) Fan, Yoko Fujimoto, Michel Grothe, Ibrahim Hakan Gürvit, Spencer Guthrie, Harald Hampel,  et al.
Dedication, Page xix
Chapter 1 - The Epidemiology and Prevention of Alzheimer’s Disease and Projected Burden of Disease, Pages 3-20, Tiia Ngandu, Francesca Mangialasche, Miia Kivipelto
Chapter 2 - Developing a National Plan to Address Alzheimer’s Disease: Are there lessons that emerging countries can learn from Western countries?, Pages 21-32, Menghis Bairu
Chapter 3 - Preventing Alzheimer’s Disease, Pages 33-46, Roy W. Jones
Chapter 4 - Overview of Global Clinical Trials: Drivers/Issues/Opportunities of Globalization, Pages 49-58, Menghis Bairu, Sidney A. Spector, Richard Chin
Chapter 5 - Challenges and Opportunities to Conduct Global Alzheimer’s Disease Clinical Trials, Pages 61-75, Jeffrey Cummings, Kate Zhong
Chapter 6 - Lessons Learned from Major Clinical Trials Conducted Over the Past Decades, Pages 77-97, Peter Schüler, Klaudius Siegfried, Michael Hüll
Chapter 7 - Why the Negative Studies in Alzheimer’s Disease?, Pages 99-116, Hans J. Möbius
Chapter 8 - The Regulatory Environment Surrounding Alzheimer’s Disease Research: FDA and EMA Guidance, Pages 119-127, Muriel O’ Byrne, Menghis Bairu
Chapter 9 - Standardization of MRI and Amyloid Imaging, Pages 131-156, Michel Grothe, Jens Kurth, Harald Hampel, Bernd J. Krause, Stefan Teipel
Chapter 10 - Operationalization of Global Alzheimer’s Disease Trials, Pages 159-177, Lynne Hughes, Spencer Guthrie
Chapter 11 - Alzheimer’s Disease Mortality and Patient Retention in Clinical Trials: The Impact of Alzheimer’s Disease on Mortality, Pages 179-195, H. Michael Arrighi
Chapter 12 - Minimizing Trial Costs by Accelerating and Improving Enrollment and Retention, Pages 197-215, Debbie N. Cote
Chapter 13 - South America’s AD Clinical Trials Experience: Lessons Learned from Argentina and Brazil, Pages 219-230, Ricardo F. Allegri, Pablo Bagnati, Sonia Brucki, Ricardo Nitrini
Chapter 14 - Dementia Clinical Research in India, Pages 231-246, Tal Burt, Lynne Hughes, Amir Kalali, P. Murali Doraiswamy
Chapter 15 - Alzheimer’s Disease Clinical Trials in China, Pages 247-262, James (Dachao) Fan, Li Huafang, Jing Yin
Chapter 16 - Lessons Learned: Alzheimer’s Disease Clinical Trials in Eastern Europe, Pages 263-275, Lynne Hughes
Chapter 17 - Experience in Alzheimer’s Disease Clinical Trials in Turkey, Pages 277-288, Yağız Üresin, Hilal İlbars, İbrahim Hakan Gürvit, Murat Emre
Chapter 18 - Strengthening/Building Alzheimer’s Disease Global Clinical Trial Site Capabilities and Capacity in and for Emerging Markets. Lessons Learned from Japan, Pages 289-304, Yoko Fujimoto, Takeshi Iwatsubo
Chapter 19 - Strengthening/Building Alzheimer’s Disease Global Clinical Trial Site Capabilities and Capacity in and for Developing/Emerging Markets. Lessons Learned from Korea, Pages 305-323, Seong Yoon Kim
Chapter 20 - Pharmacogenomics in Developing Countries: Challenges and Opportunities, Pages 327-351, Sidney A. Spector
Chapter 21 - Application of Pharmacogenomics in Global Alzheimer’s Disease Clinical Trials and Ethical Implications, Pages 353-370, Sidney A. Spector
Chapter 22 - Long-Term Human Resources Planning for Alzheimer’s Disease Trials, Pages 373-394, Nadina C. Jose, Lorne Cheeseman, Stephanie Danandjaja
Index, Pages 395-407